Tuesday, April 29, 2025 6:16:19 AM
Everyone assumes that the NWBO MAA is backlogged.
(1) That assumption is wrong. According to the MHRA (as of 31 March 2025), not a single application is backlogged. Read this from the MHRA:
"On 31 March 2025, we cleared all backlogs related to licence applications for innovative and established medicines. All new national licence applications submitted after 1 September 2024 continue to be assessed within our target of 210 days, with an average timescale of 160 days in March."
2) According to the MHRA the DCVax-L application is not considered backlogged because NOT a single application is backlogged. The DCVax-L application review is off the clock and, therefore, under MHRA definitions, it is not classified as backlogged. ("Backlogged," according to the MHRA, means the MHRA is responsible for the delay not the company.)
(3) Thus, the real question is: why is the DCVax-L application off the clock?
A. They have been approved, but we haven't heard that so thats off the table for now.
B. The only plausible reason is that NWBO received another RFI (Request for Information). This is a factual deduction based on real-world information and timelines. This deduction also aligns with NWBO's own statement in their April 1, 2025 10-K filing, where they wrote:
"The Company continued working with teams of specialized consultants on the MAA process, including onsite inspections in the U.K. and U.S., and ongoing production of documents and information before, during, and after the inspections."
(4) Timeline from here on:
A. It is likely that NWBO received another RFI stemming from the on-site clinical trial inspections conducted by the MHRA between mid-September 2024 and the end of February 2025. Preparing that RFI and sending it to NWBO would have taken time, likely occurring around mid- to late-March 2025 — just before NWBO’s last 10-K was filed. Let's assume that NWBO will take about two months to answer this RFI. They would therefore submit their response just before ASCO (early June), which would also explain why NWBO canceled their ASCO presence and said they want to stay focused on the application.
B. After NWBO submits their response, the MHRA review clock will start running again.
If the MHRA then takes around 60 days for final review, that would put a possible decision around the end of July 2025.
It sucks but that is really where we are now.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
